Amgen’s Q3 Sales Beat Consensus, But Two Key New Drugs Fell Short

 
• By Mandy Jackson
  
Business report
Aimovig and Repatha were below consensus, but Enbrel, Evenity and biosimilars beat expectations. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business